# Preoperative oral treatment with cyclooxygenase‐2 inhibitor for cystitis glandularis

## TL;DR

A COX-2 inhibitor reduced tumor volume in a patient with cystitis glandularis before surgery, improving symptoms and enabling successful treatment.

## Contribution

Demonstrates the effectiveness of preoperative COX-2 inhibition in reducing cystitis glandularis tumor volume.

## Key findings

- Oral administration of a COX-2 inhibitor significantly reduced tumor volume in a patient with cystitis glandularis.
- Symptoms like voiding difficulty and pain improved after COX-2 inhibitor treatment.
- COX-2 inhibition may serve as a useful preoperative strategy for cystitis glandularis.

## Abstract

A previous report has shown that cyclooxygenase‐2 inhibitors can prevent the recurrence of cystitis glandularis postoperatively. Herein, we present a case of cystitis glandularis in which the tumor volume was markedly reduced by preoperative oral administration of a cyclooxygenase‐2 inhibitor.

A 45‐year‐old man with voiding difficulty and lower abdominal pain during urination was referred to our hospital. Cystoscopy revealed multiple cystitis glandularis‐like edematous masses on the trigone and the neck of the bladder, completely involving the bilateral ureteral orifices. Cyclooxygenase‐2 inhibitor was orally administered at the patient's request. Six weeks later, the tumor volume was markedly reduced, bilateral ureteral orifices were identified, and the voiding difficulty and pain on urination disappeared. Complete transurethral resection of the residual tumor was performed, and the pathological diagnosis was intestinal‐type cystitis glandularis.

Cyclooxygenase‐2 inhibition can be considered a useful therapeutic strategy for cystitis glandularis.